Does Ozempic Cause Depression?

Short answer: No, based on the current evidence. The FDA investigated this exact question through 2024 and 2025 and, on January 13, 2026, formally requested that the suicidal-behavior-and-ideation warning be removed from the three GLP-1 receptor agonist labels that had ever carried it — Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide), all three approved for chronic weight management. The diabetes-only GLP-1s (Ozempic, Mounjaro, Victoza, Rybelsus) never had a suicidal-ideation warning on their labels — that requirement is an FDA class rule specific to drugs approved for chronic weight management that act on the central nervous system. Multiple large-scale pharmacovigilance studies, including an FDA meta-analysis of 91 clinical trials with 107,910 participants, have failed to find a causal link between the GLP-1 receptor agonist class and increased suicidality. Early 2026 data is even suggesting semaglutide may have modest positive effects on certain aspects of depression.

Long answer is more interesting, and worth understanding if you're on a GLP-1 drug, considering starting one, or — most relevant for many of our patients — taking a GLP-1 while also being treated for depression or considering ketamine therapy.

The arc of the concern

In July 2023, the European Medicines Agency announced it was reviewing case reports of suicidal ideation in patients taking GLP-1 receptor agonists, prompted by signals from Iceland's drug surveillance system. The FDA followed with its own review in September 2023, requesting post-marketing data from manufacturers. The agencies acknowledged that case reports do not establish causation, but the volume of reports was high enough to warrant a formal investigation.

For roughly two years after that announcement, every patient starting Ozempic or Wegovy heard some version of the question: "Wait, will this make me suicidal?" Online forums filled with anecdotes — some genuinely concerning, many ambiguous (was the depression from the drug, or from the underlying obesity/diabetes, or from the appetite change itself?). It became one of the most-asked questions in obesity medicine clinics, and one of the most cited concerns from patients hesitating to start treatment.

What the data actually shows

The FDA's January 2024 preliminary finding

In January 2024, the FDA released a preliminary statement saying its initial review of FAERS (FDA Adverse Event Reporting System) data and clinical trial data had not found evidence that GLP-1 receptor agonists cause suicidal thoughts or actions. The agency continued investigating throughout 2024 and 2025.

The large-scale studies

Several rigorous studies have been published since the investigation began:

A large pharmacovigilance analysis published in 2026 compared suicidality-related adverse event reporting rates between GLP-1 receptor agonists and non-GLP-1 anti-obesity drugs and found no significant signal for the GLP-1 class as a whole.¹

A separate FDA Sentinel Distribution study examined intentional self-harm in patients with type 2 diabetes on GLP-1 receptor agonists vs. comparator antidiabetic medications. The study, published in BMJ Open Diabetes Research & Care in early 2026, found no increased risk of intentional self-harm associated with GLP-1 RA use.²

A comprehensive 2026 review in Biological Psychiatry synthesized the available evidence on GLP-1 receptor agonists' implications for mood disorders and suicide risk, and concluded that while case reports exist (and individual patients can certainly experience mood changes on any medication), the population-level evidence does not support a causal link between GLP-1 use and increased suicidality.³

The FDA's January 2026 conclusion

On January 13, 2026, after the cumulative evidence had been reviewed, the FDA went a step further than just dropping the investigation: the agency issued a drug-safety communication formally requesting removal of the suicidal-behavior-and-ideation warning from the three GLP-1 receptor agonist labels that had carried it — Saxenda, Wegovy, and Zepbound.⁴ The basis was an FDA meta-analysis of 91 clinical trials across the GLP-1 development programs, including 107,910 participants (60,338 on a GLP-1, 47,752 on placebo), which found no increased risk of suicidal ideation, behavior, or related psychiatric adverse events compared with placebo.

It's worth being precise about which drugs ever carried that warning. The diabetes-indicated GLP-1s (Ozempic, Mounjaro, Victoza, Rybelsus) never had a suicidal-ideation warning on their labels. The warning was an FDA class requirement specific to drugs approved for chronic weight management that act on the central nervous system — a category that includes Saxenda, Wegovy, and Zepbound but not their diabetes-only counterparts. The January 2026 communication is the strongest possible signal the FDA can send short of a positive endorsement — it's the regulatory equivalent of saying "we looked hard, and there isn't a there there."

So why did patients report depression on these drugs?

This is where the picture gets more nuanced. "No causal link in the population" doesn't mean "no patient ever has a mood change on a GLP-1 drug." Three things are likely happening in the case reports:

1. Rapid weight loss changes things

Major weight loss — particularly the rapid, sustained weight loss that GLP-1 drugs produce — is itself a profound psychological event. Body image shifts, relationships change, identity recalibrates. Some patients describe mood disturbance during periods of rapid weight change regardless of the mechanism of weight loss. Bariatric surgery patients have similar reports.

2. The "food noise" change is real and underappreciated

GLP-1 drugs dramatically reduce what patients call "food noise" — the constant low-level mental activity around what to eat, when, how much. For most patients this is liberating. For some, food has been a primary emotional regulation tool for years, and losing that tool without replacement coping skills can leave a real psychological hole. It's not depression caused by the drug — it's depression that was being managed by a coping behavior the drug removed.

3. Pre-existing depression unmasked by the conversation

When patients start a new medication, particularly one that requires close follow-up, depression that was already present often becomes more visible. Some of what looks like "GLP-1 caused depression" is really "GLP-1 surfaced depression that was being managed without anyone noticing."

None of this means individual cases of mood worsening on GLP-1 should be ignored. They shouldn't. But the data tells us these are not a drug-caused population-level effect.

The emerging positive signal

Here's where the 2026 story takes an interesting turn. A randomized clinical trial published in JAMA Psychiatry in 2026 examined the effect of semaglutide on effort-based decision-making in patients with major depressive disorder — a specific cognitive domain that's commonly impaired in depression.⁵ The result: semaglutide was associated with measurable improvement in this domain compared to placebo, independent of weight loss.

This is preliminary, single-trial data — not yet enough to recommend GLP-1 drugs for depression. But it raises an interesting mechanistic question. GLP-1 receptors exist throughout the brain, including in regions involved in reward processing, motivation, and inflammation. Several research groups are now exploring whether the GLP-1 receptor agonist class might have direct CNS effects relevant to mood disorders, beyond what weight loss alone would predict.

What this means for ketamine therapy patients

This is where we see this question most often in our practice: a patient is on Ozempic, Wegovy, or Mounjaro, considering at-home ketamine therapy for depression, and wants to know whether the combination is safe and whether one will interfere with the other.

Three honest answers:

1. There's no pharmacological interaction between GLP-1 receptor agonists and ketamine. They work through entirely different mechanisms — GLP-1 RAs at the glucagon-like peptide-1 receptor (mostly in gut, pancreas, and various CNS regions); ketamine at the NMDA glutamate receptor. No CYP metabolism overlap, no shared transport pathway, no clinically meaningful PK or PD interaction. This is covered in detail on our drug interactions guide for GLP-1 medications and on the semaglutide drug-interactions page.

2. The practical considerations are real but manageable. GLP-1 drugs cause nausea, especially early in treatment and after dose increases. Ketamine sessions involve fasting (4-6 hours before) and can themselves cause some nausea. Stacking these without thought makes for a miserable session. We coordinate session timing with where you are in your GLP-1 dose-escalation cycle.

3. If you experienced mood changes on the GLP-1 drug, tell us. Even if the population data says GLP-1s don't cause depression, your individual experience matters. Some patients describe mood changes that started with the GLP-1 and worsened around the timing of dose escalations — even if the population data doesn't show a causal link, the individual signal is worth understanding before we plan a ketamine course. We'd rather know than not.

When to talk to your prescriber

If you're on a GLP-1 drug and experiencing any of these, talk to whoever prescribed it:

• New onset depression that wasn't present before starting the drug, especially developing in the first few weeks or after a dose increase
• Suicidal thoughts of any kind, at any time — this is true regardless of whether the drug caused them, and regardless of whether you have a history of depression
• Loss of pleasure in things you previously enjoyed, beyond what you'd attribute to the appetite reduction
• Sleep changes that don't resolve as your body adapts to the medication
• Increased anxiety that's interfering with daily life

The 2025 FDA position is that GLP-1 drugs don't cause these in the population. That doesn't mean they can never happen in an individual patient on a GLP-1 drug. It means the medical community shouldn't withhold useful treatment based on a fear that isn't supported by population data — but should still take individual patient experiences seriously.

Frequently asked questions

Is the FDA black box warning for depression still on Ozempic?

There was never a black box warning for depression on any GLP-1 drug, and Ozempic itself never carried a suicidal-ideation warning of any kind. The warning that did exist appeared only on the three weight-loss-indicated GLP-1s — Saxenda, Wegovy, and Zepbound — in their Warnings and Precautions section, not as a boxed (black box) warning. The diabetes-indicated GLP-1s (Ozempic, Mounjaro, Victoza, Rybelsus) were never subject to the FDA's class rule on suicidal-ideation monitoring for CNS-acting chronic weight management drugs. On January 13, 2026 the FDA formally requested removal of the warning from the labels of Saxenda, Wegovy, and Zepbound.⁴

Can Mounjaro and Zepbound cause depression?

Both are tirzepatide (Mounjaro for diabetes; Zepbound for obesity). The same evidence that exonerated the GLP-1 class for depression risk applies to tirzepatide. There's slightly less long-term population data for tirzepatide than for semaglutide simply because it's a newer drug, but the available evidence has not shown a depression signal.

Should I stop my GLP-1 drug before starting ketamine therapy?

No, you should not stop a GLP-1 drug just because you're starting ketamine therapy. The two can be taken together. We coordinate session timing around the GLP-1 dose schedule (particularly around dose increases when nausea is highest) and ensure you have appropriate fasting and anti-nausea support if needed.

I'm on antidepressants AND a GLP-1 drug. Is that a problem?

No. Combining antidepressants (SSRIs, SNRIs, bupropion, others) with GLP-1 drugs is common and not associated with specific interaction concerns. If you're considering adding ketamine therapy on top of this, that's a separate conversation, and we cover the specifics for SSRIs, SNRIs, and other antidepressants in our drug interactions guide.

Does compounded semaglutide or compounded tirzepatide carry different risk?

The active molecule is the same. The risk concerns with compounded versions are quality-control and concentration accuracy issues, not different pharmacological risks. If you're on a compounded GLP-1, the mood-effect question is identical to the brand-name form, but the broader safety question (sterility, dose accuracy) is real and worth discussing with your prescriber.

The bottom line

The 2024 concern was reasonable to investigate. The January 2026 conclusion from the FDA, supported by multiple large-scale studies and an internal meta-analysis of 91 trials and 107,910 participants, is that GLP-1 receptor agonists do not cause depression or increased suicidality in the general patient population on these drugs. Early 2026 data is even suggesting modest positive effects of semaglutide on certain aspects of depression.

Individual patients can absolutely experience mood changes on any medication, including GLP-1s. Those changes deserve attention. But the population-level data does not support the kind of class-wide concern that the FDA was investigating in 2023-2024.

If you're on a GLP-1 drug and considering ketamine therapy for depression or another condition, the interaction is favorable, the timing is coordinable, and the combination is one we see often. Check your eligibility if you'd like to talk it through with a physician.

---

References

---

Reviewed by Benjamin Soffer, DO. This article provides general medical information about GLP-1 receptor agonists and mood, and is not a substitute for medical advice about your specific situation. If you're experiencing depression or suicidal thoughts, contact your physician, the 988 Suicide and Crisis Lifeline (call or text 988), or seek emergency care. If you're considering ketamine therapy alongside a GLP-1 medication, start with our eligibility check or contact us.

Footnotes

1. Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs. International Journal of Clinical Pharmacy, 2026. PMID 41739406 ↩

2. Association of GLP-1 receptor agonists with intentional self-harm in patients with type 2 diabetes: a Sentinel Distribution study. BMJ Open Diabetes Research & Care, 2026. PMID 41850718 ↩

3. Implications of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) for Mood Disorders and Suicide Risk. Biological Psychiatry, 2026. PMID 42069105 ↩

4. FDA Requests Removal of Suicidal Ideation Warning From GLP-1 RA Medications. JAMA, 2026. PMID 41615669 ↩ ↩²

5. Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 2026. PMID 42054055 ↩